Pharma BD Deal Intelligence

Avextra AG / SynQube GmbH

2024 · Co-Development · Complete

Avextra AG and SynQube GmbH announced a strategic partnership for joint development of cannabinoid- and other psychotropic-substance-based medicines, with SynQube developing manufacturing processes and Avextra acting as industry partner for a planned five-site EU multi-center clinical trial of a psilocybin-based compound from 2025. Financial terms were not disclosed; the companies flagged potential future reciprocal equity investment.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Announced Jun 20, 2024
Deal type Co-Development

Related deals

Novo Holdings A/S / Catalent (manufacturing sites) (2024)
Novartis AG / PTC Therapeutics Inc. (2024)
Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences (2024)
Johnson & Johnson / Shockwave Medical (2024)
Gilead Sciences Inc. / CymaBay Therapeutics (2024)
AstraZeneca PLC / Amolyt Pharma (2024)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2024 deals